CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Adjusts Price Target on Tandem Diabetes Care to $18 From $22, Maintains Neutral Rating

Negative
AI Analysis

Summary

UBS reduced its price target on Tandem Diabetes Care from $22 to $18 while maintaining a Neutral rating on the stock.

Importance:3/10
Sentiment:
-0.30
price_target_reductionanalyst_downgrade_action
Related Companies

Read the original article

Published by yahoo_finance on July 28, 2026 2:40 PM

Read Original